-+ 0.00%
-+ 0.00%
-+ 0.00%
DKSH says Singapore approves HPV cervical lesion spray gel Colpofix
Share
Listen to the news
DKSH says Singapore approves HPV cervical lesion spray gel Colpofix
  • DKSH Healthcare secured Singapore regulatory clearance for Colpofix, a prescription vaginal spray gel device targeting HPV-related cervical lesions.
  • The approval supports a commercial launch in Singapore, adding a new women’s health product to DKSH’s regional healthcare portfolio.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DKSH Holding AG published the original content used to generate this news brief on September 21, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending